S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NYSE:AGE - AgeX Therapeutics Stock Price, Forecast & News

$1.85
+0.06 (+3.35 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$1.79
Now: $1.85
$1.95
50-Day Range
$1.25
MA: $1.60
$1.95
52-Week Range
$1.16
Now: $1.85
$4.99
Volume92,822 shs
Average Volume83,185 shs
Market Capitalization$69.65 million
P/E RatioN/A
Dividend YieldN/A
Beta4.42
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone510-671-8370

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.40 million
Book Value$0.23 per share

Profitability

Net Income$-7,500,000.00
Net Margins-846.45%

Miscellaneous

EmployeesN/A
Market Cap$69.65 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.


AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics (NYSE:AGE) issued its quarterly earnings data on Thursday, November, 14th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.41 million for the quarter. AgeX Therapeutics had a negative return on equity of 165.04% and a negative net margin of 846.45%. View AgeX Therapeutics' Earnings History.

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for AgeX Therapeutics.

Has AgeX Therapeutics been receiving favorable news coverage?

Media coverage about AGE stock has been trending somewhat positive on Friday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AgeX Therapeutics earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AgeX Therapeutics.

Who are some of AgeX Therapeutics' key competitors?

What other stocks do shareholders of AgeX Therapeutics own?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the folowing people:
  • Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
  • Dr. Michael D. West, Pres, CEO & Director (Age 65)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Nafees Naseer Malik, Chief Operating Officer
  • Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $1.85.

How big of a company is AgeX Therapeutics?

AgeX Therapeutics has a market capitalization of $69.65 million and generates $1.40 million in revenue each year. View Additional Information About AgeX Therapeutics.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is http://www.agexinc.com/.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510-671-8370.


MarketBeat Community Rating for AgeX Therapeutics (NYSE AGE)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote "Outperform" if you believe AGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel